Immuneering Financial Statements From 2010 to 2025

Stocks USA . 
Stock . Immuneering Corp
IMRX Stock  USD 1.86  0.04  2.20%   
Immuneering Corp financial statements provide useful quarterly and yearly information to potential Immuneering Corp investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Immuneering Corp financial statements helps investors assess Immuneering Corp's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Immuneering Corp's valuation are summarized below:
Gross Profit
158.8 K
Market Capitalization
57.8 M
Enterprise Value Revenue
191.9 K
Revenue
455
Earnings Share
(1.97)
We have found one hundred twenty available fundamental trends for Immuneering Corp, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to confirm all of Immuneering Corp regular market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 365.2 M in 2025. Enterprise Value is likely to rise to about 315.5 M in 2025

Immuneering Corp Total Revenue

389.03

Check Immuneering Corp financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immuneering Corp's main balance sheet or income statement drivers, such as Net Interest Income of 4.1 M, Interest Income of 4.1 M or Depreciation And Amortization of 425.1 K, as well as many indicators such as Price To Sales Ratio of 207, Dividend Yield of 0.0 or PTB Ratio of 2.18. Immuneering financial statements analysis is a perfect complement when working with Immuneering Corp Valuation or Volatility modules.
  
Check out the analysis of Immuneering Corp Correlation against competitors.
For more information on how to buy Immuneering Stock please use our How to Invest in Immuneering Corp guide.

Immuneering Corp Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets97.7 M118 M49.2 M
Slightly volatile
Short and Long Term Debt Total5.1 M4 M11.9 M
Slightly volatile
Other Current Liabilities3.3 M6.2 M1.6 M
Slightly volatile
Total Current Liabilities5.3 M9 M2.7 M
Slightly volatile
Property Plant And Equipment Net4 M6.2 M1.8 M
Slightly volatile
Accounts Payable1.9 M2.4 M960.9 K
Slightly volatile
Cash56.7 M68.3 M31.7 M
Slightly volatile
Non Current Assets Total9.3 M15.5 M4.2 M
Slightly volatile
Cash And Short Term Investments86.1 M98.5 M43.7 M
Slightly volatile
Common Stock Total Equity17.2 K30.4 K11.3 K
Slightly volatile
Common Stock Shares Outstanding29.1 M32.7 M26.5 M
Slightly volatile
Liabilities And Stockholders Equity97.7 M118 M49.2 M
Slightly volatile
Non Current Liabilities Total3.6 M3.7 M17.6 M
Slightly volatile
Other Current Assets2.1 M3.9 M1 M
Slightly volatile
Total Liabilities18.7 M10.8 M20.7 M
Pretty Stable
Property Plant And Equipment Gross7.4 M7 M1.5 M
Slightly volatile
Total Current Assets88.4 M102.4 M45 M
Slightly volatile
Capital Stock20.2 K33.7 K11.9 K
Slightly volatile
Net Working Capital83.1 M93.4 M42.3 M
Slightly volatile
Common Stock20.2 K33.7 K11.9 K
Slightly volatile
Property Plant Equipment794.6 K1.6 M434.1 K
Slightly volatile
Other Assets1.091.1562.7 K
Pretty Stable
Short Term Debt283 K345.1 K151.3 K
Slightly volatile
Capital Surpluse239.2 M252.6 M219.6 M
Slightly volatile
Intangible Assets327.4 K341.7 K420.4 K
Slightly volatile
Current Deferred Revenue4.1 M4.7 M5.1 M
Slightly volatile

Immuneering Corp Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income4.1 M3.9 M819.7 K
Slightly volatile
Interest Expense1.2 M1.2 M511.1 K
Slightly volatile
Selling General Administrative10.2 M19.3 M6.3 M
Slightly volatile
Total Revenue3894101.5 M
Slightly volatile
Other Operating Expenses38.3 M67.2 M22.1 M
Slightly volatile
Research Development27.2 M47.6 M14.8 M
Slightly volatile
Cost Of Revenue732.6 K687.7 K1.1 M
Slightly volatile
Total Operating Expenses37.3 M66.3 M21 M
Slightly volatile
Reconciled Depreciation1 M987.5 K256.2 K
Slightly volatile
Selling And Marketing Expenses409.5 K460.7 K502.3 K
Slightly volatile

Immuneering Corp Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Change To Inventory14 K15.8 K17.2 K
Slightly volatile
Net Borrowings3.1 M3.4 M3.8 M
Slightly volatile
Stock Based Compensation6.9 M6.6 M2 M
Slightly volatile
Begin Period Cash Flow43.9 M83.5 M21 M
Slightly volatile
Depreciation309.2 K404.9 K142.6 K
Slightly volatile
Capital Expenditures268.4 K394.2 K129.2 K
Slightly volatile
Issuance Of Capital Stock55.6 M32.4 M28.8 M
Slightly volatile
Total Cash From Financing Activities36.5 M25.6 M27.8 M
Slightly volatile
End Period Cash Flow56.7 M68.3 M31.7 M
Slightly volatile
Change To Netincome2.6 M4.7 M2.9 M
Pretty Stable
Sale Purchase Of Stock16.2 K17.1 K108.2 M
Slightly volatile
Change Receivables205.3 K210.3 K265 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio207363257
Slightly volatile
Days Sales Outstanding15.6216.4436.3731
Slightly volatile
Average Payables1.4 M2.4 M1.2 M
Slightly volatile
Stock Based Compensation To Revenue12.1211.543.3595
Slightly volatile
Capex To Depreciation0.91.121.0209
Slightly volatile
EV To Sales213218220
Slightly volatile
Days Of Inventory On Hand0.00180.00210.0023
Slightly volatile
Payables Turnover0.40.422.7742
Slightly volatile
Sales General And Administrative To Revenue46.5344.3213.0476
Slightly volatile
Average Inventory0.40.450.4906
Slightly volatile
Research And Ddevelopement To Revenue10810330.0937
Slightly volatile
Capex To Revenue2.212.110.5728
Slightly volatile
Cash Per Share2.352.711.5374
Slightly volatile
Days Payables Outstanding1.5 K908776
Slightly volatile
Income Quality0.660.820.6756
Slightly volatile
Intangibles To Total Assets0.04530.0620.0468
Slightly volatile
Current Ratio21.2213.0623.8263
Slightly volatile
Receivables Turnover24.1222.9712.6661
Slightly volatile
Graham Number6.8610.464.5201
Slightly volatile
Capex Per Share0.00730.01090.0044
Slightly volatile
Average Receivables6.8 K7.1 K106.3 K
Slightly volatile
Revenue Per Share0.01310.01380.0608
Slightly volatile
Interest Debt Per Share0.280.180.4822
Slightly volatile
Debt To Assets0.04750.050.7507
Slightly volatile
Operating Cycle15.6216.4536.374
Slightly volatile
Days Of Payables Outstanding1.5 K908776
Slightly volatile
Ebt Per Ebit1.121.051.1445
Slightly volatile
Long Term Debt To Capitalization1.321.481.6163
Slightly volatile
Quick Ratio21.2213.0623.8263
Slightly volatile
Net Income Per E B T1.11.121.038
Very volatile
Cash Ratio16.198.7121.4987
Slightly volatile
Days Of Inventory Outstanding0.00180.00210.0023
Slightly volatile
Days Of Sales Outstanding15.6216.4436.3731
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.810.910.9872
Slightly volatile
Fixed Asset Turnover0.05990.063134.2613
Slightly volatile
Debt Ratio0.04750.050.7507
Slightly volatile
Price Sales Ratio207363257
Slightly volatile
Asset Turnover0.00280.0030.0903
Slightly volatile
Gross Profit Margin0.350.450.3952
Slightly volatile

Immuneering Corp Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap365.2 M240.2 M394 M
Slightly volatile
Enterprise Value315.5 M177 M374.5 M
Slightly volatile

Immuneering Fundamental Market Drivers

Cash And Short Term Investments85.7 M

Immuneering Upcoming Events

4th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Immuneering Corp Financial Statements

Immuneering Corp investors use historical fundamental indicators, such as Immuneering Corp's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immuneering Corp. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue4.7 M4.1 M
Total Revenue 409.50  389.03 
Cost Of Revenue687.7 K732.6 K
Stock Based Compensation To Revenue 11.54  12.12 
Sales General And Administrative To Revenue 44.32  46.53 
Research And Ddevelopement To Revenue 102.98  108.13 
Capex To Revenue 2.11  2.21 
Revenue Per Share 0.01  0.01 
Ebit Per Revenue(187.75)(178.36)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
CSXCSX Corporation
ETONEton Pharmaceuticals
ALLTAllot Communications

Additional Tools for Immuneering Stock Analysis

When running Immuneering Corp's price analysis, check to measure Immuneering Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immuneering Corp is operating at the current time. Most of Immuneering Corp's value examination focuses on studying past and present price action to predict the probability of Immuneering Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immuneering Corp's price. Additionally, you may evaluate how the addition of Immuneering Corp to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY